Ignite Creation Date:
2024-05-06 @ 5:40 PM
Last Modification Date:
2024-10-26 @ 2:33 PM
Study NCT ID:
NCT05383014
Status:
UNKNOWN
Last Update Posted:
2022-05-19
First Post:
2022-05-17
Brief Title:
FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
Assessment of Association Between FLT3-ITD Gene Mutation and CD135 Expression and Their Correlation With HematologicalImmunophenotypic and Biochemical Characteristics in Acute Myeloid Leukemia
Status:
UNKNOWN
Status Verified Date:
2022-05
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
1 To evaluate expression levels of CD135
2 To assess the frequency of FLT3 gene mutations ITD
3 association between FLT3-ITD mutation and CD135 expression and their correlation with hematological immunophenotypicand biochemical features
2 To assess the frequency of FLT3 gene mutations ITD
3 association between FLT3-ITD mutation and CD135 expression and their correlation with hematological immunophenotypicand biochemical features
Detailed Description:
Acute leukemias are clonal malignant diseases of immature hematopoietic system characterized by clonal evolution and considerable genetic epigenetic and phenotypic heterogeneityand constitute a common cause of morbidity and mortality worldwide1 Gene expression profiling has improved the molecular classification and prognosis of Acute leukemias where molecular testing has become mandatory for further classify into prognostic groups Among the genetic aberrations alterations of the FMS-like tyrosine kinase 3 FLT3 gene 2 FLT3 is a type 3 receptor tyrosine kinase that plays an important role in the expansion and proliferation of multi-potent progenitor cells within the bone marrow3 mutations of FLT3 induce a constitutional activation of tyrosine kinases and several downstream targets resulting in proliferation and growth of malignant cells myeloproliferative phenotype high tumor burdenand a characteristic hematological immunophenotypic and biochemical profile that can be identified during routine diagnostic workup4Two mutations exist in these cells FLT3-ITD internal tandem duplication and FLT3-TKD a point mutation in the tyrosine kinase domain5 FLT3-ITD is a common driver mutation seen with a frequency of 20 to 30 and significantly affecting the pathogenesis and the clinical outcome Genetic testing for FLT3-ITD mutation at diagnosis is done to risk stratify patients and to guide therapeutic decisions6-8 FLT3 receptorCD135 is a transmembrane tyrosine kinase receptor normally expressed on the surface of hematopoietic stem cells and is lost upon cell differentiation activation of the receptor resulting in stimulating survival and proliferation and inhibiting apoptosis of progenitor cells Overexpression of the FLT3 receptor has been reported to be associated with high risk for relapse in patients with acute leukemia 2
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None